Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
- Conditions
- Multiple MyelomaNon-Hodgkin LymphomaHodgkin Disease
- Interventions
- Other: AcupunctureDrug: opioidOther: Assessments
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 299
- Registration Number
- NCT04459416
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Seattle Cancel Care Alliance (Data Collection Only), Seattle, Washington, United States
Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer
- Conditions
- High Grade Ovarian SerousOvarian Cancer
- Interventions
- Diagnostic Test: PET/MRIDiagnostic Test: Contrast enhanced CT
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04454450
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
A New Psychotherapy Intervention for Older Cancer Patients
- Conditions
- Cancer
- Interventions
- Behavioral: Social Work and Supportive Counseling (SWSC) Intervention
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 409
- Registration Number
- NCT04452825
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04447768
- Locations
- 🇺🇸
Stanford University Medical Center (Data collection only), Stanford, California, United States
🇺🇸Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
- Conditions
- Well-differentiated/Dedifferentiated Liposarcoma
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT04438824
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Avatrombopag for Thrombocytopenia in People With Cancer
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT04437953
Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer
- Conditions
- Advanced Cancer
- Interventions
- Other: Attention control supportive careOther: Masterful supportive care
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT04435444
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of the Life Changes Experienced by Patients With Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Behavioral: Measurement of Transitions in Cancer Scale (MOT-CA) SurveyBehavioral: Distress Thermometer Survey
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT04427761
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
- Conditions
- Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04419519
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
- Conditions
- Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT04416451
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All protocol Activities), Montvale, New Jersey, United States